258 related articles for article (PubMed ID: 30610562)
1. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma.
Pandit H; Hong YK; Li Y; Rostas J; Pulliam Z; Li SP; Martin RCG
Ann Surg Oncol; 2019 Mar; 26(3):800-806. PubMed ID: 30610562
[TBL] [Abstract][Full Text] [Related]
2. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
3. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.
Kluger MD; Epelboym I; Schrope BA; Mahendraraj K; Hecht EM; Susman J; Weintraub JL; Chabot JA
Ann Surg Oncol; 2016 May; 23(5):1736-43. PubMed ID: 26714959
[TBL] [Abstract][Full Text] [Related]
4. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
Martin RC; McFarland K; Ellis S; Velanovich V
J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
[TBL] [Abstract][Full Text] [Related]
5. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
O'Neill C; Hayat T; Hamm J; Healey M; Zheng Q; Li Y; Martin RCG
Surgery; 2020 Oct; 168(4):610-616. PubMed ID: 32631655
[TBL] [Abstract][Full Text] [Related]
7. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.
Martin RC; McFarland K; Ellis S; Velanovich V
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S443-9. PubMed ID: 23128941
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
9. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer.
Yamamoto T; Yanagimoto H; Satoi S; Toyokawa H; Hirooka S; Yamaki S; Yui R; Yamao J; Kim S; Kwon AH
Pancreas; 2012 Apr; 41(3):409-15. PubMed ID: 22158072
[TBL] [Abstract][Full Text] [Related]
10. Real-time prediction of patient immune cell modulation during irreversible electroporation therapy.
Beitel-White N; Martin RCG; Li Y; Brock RM; Allen IC; Davalos RV
Sci Rep; 2019 Nov; 9(1):17739. PubMed ID: 31780711
[TBL] [Abstract][Full Text] [Related]
11. Immunological effect of irreversible electroporation on hepatocellular carcinoma.
Guo X; Du F; Liu Q; Guo Y; Wang Q; Huang W; Wang Z; Ding X; Wu Z
BMC Cancer; 2021 Apr; 21(1):443. PubMed ID: 33882892
[TBL] [Abstract][Full Text] [Related]
12. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
[TBL] [Abstract][Full Text] [Related]
13. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.
Marsanic P; Mellano A; Sottile A; De Simone M
Med Biol Eng Comput; 2017 Jul; 55(7):1123-1127. PubMed ID: 28078482
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of preoperative immunonutrition in locally advanced pancreatic cancer undergoing irreversible electroporation (IRE).
Martin RC; Agle S; Schlegel M; Hayat T; Scoggins CR; McMasters KM; Philips P
Eur J Surg Oncol; 2017 Apr; 43(4):772-779. PubMed ID: 28162818
[TBL] [Abstract][Full Text] [Related]
15. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
[TBL] [Abstract][Full Text] [Related]
16. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.
Ikemoto T; Shimada M; Komatsu M; Yamada S; Saito Y; Mori H; Morine Y; Imura S; Bando Y; Utsunomiya T
Pancreas; 2013 Jan; 42(1):130-4. PubMed ID: 22722263
[TBL] [Abstract][Full Text] [Related]
19. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Yokokawa J; Cereda V; Remondo C; Gulley JL; Arlen PM; Schlom J; Tsang KY
Clin Cancer Res; 2008 Feb; 14(4):1032-40. PubMed ID: 18281535
[TBL] [Abstract][Full Text] [Related]
20. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility.
Flak RV; Stender MT; Jensen TM; Andersen KL; Henriksen SD; Mortensen PB; Sall M; Thorlacius-Ussing O
Scand J Gastroenterol; 2019 Feb; 54(2):252-258. PubMed ID: 30907286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
